Andreas Emmenegger new Group Chief Financial Officer (CFO) and Chief Business Officer (CBO)
Promising Next-Generation SARS-CoV-2 Live Vaccine Demonstrates Remarkable Safety, Protection, and Immunity Profile in Pre-Clinical Studies
Rocketvax Announces Collaboration with the US National Institutes of Health (NIH) for Clinical Trial of Nasal, Live-Attenuated NextGen SARS-CoV-2 Vaccine
Torqur AG Announces First Patient Dosed in Phase 2 Clinical Trial of Bimiralisib in Actinic Keratosis
Swiss Biotech TORQUR AG Unveils Groundbreaking Data on New Cancer Drug Candidate Bimiralisib
New study on the benefits of COVID-19 nasal spray vaccination published in "Nature Communications"
Renowned Venture Capitalist and Angel Investor Daniel Gutenberg Joins Swiss Rockets AG’s Board of Directors and Invests in Promising Biotech Startups
Rocketvax AG selected to participate in SIX Swiss Exchange Sparks IPO Academy
Swiss Rockets AG and its subsidiary Torqur AG welcome four key scientific members
Swiss Rockets AG further advances its technologies in cooperation with Serbia
Nasal vaccine against coronavirus further improved
New vaccine concept against SARS-CoV-2 successfully tested
Torqur AG's cancer drug candidate bimiralisib with promising new study results
Swiss Rockets AG Welcomes Three New Key Members To The Team
RocketVax Nasal Vaccine to Prevent COVID-19 Passes First Tests
